2024
Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life
Proussaloglou E, Lustberg M. Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life. Current Breast Cancer Reports 2024, 16: 227-236. DOI: 10.1007/s12609-024-00548-z.Peer-Reviewed Original ResearchYoung breast cancer patientsSurvivorship careBreast cancer patientsEffectiveness of cancer careFamily planning concernsPost-partum careUnique survivorship needsQuality-of-life issuesBreast cancerQuality of lifeCancer patientsSurvivorship needsGenitourinary syndrome of menopauseCancer careDisease-free recurrenceAnti-estrogen therapyUnique group of patientsSexual healthGroup of patientsCareVaginal estrogenEndocrine therapyOverall survivalSummaryAdditional researchIatrogenic menopauseFeasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial
Buga A, Harper D, Sapper T, Hyde P, Fell B, Dickerson R, Stoner J, Kackley M, Crabtree C, Decker D, Robinson B, Krystal G, Binzel K, Lustberg M, Volek J. Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial. PLOS ONE 2024, 19: e0296523. PMID: 38166036, PMCID: PMC10760925, DOI: 10.1371/journal.pone.0296523.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerStage IV metastatic breast cancerKetogenic dietInsulin resistanceNutritional ketosisPlasma insulinBreast cancerBody compositionAdjuvant therapeutic interventionsMetabolic outcomesCancer patientsPlasma glucoseMetabolic effectsBody fatShort-term studiesBody weightPleiotropic mechanismsTherapeutic interventionsConsistent bloodPhase IMonthsWomenCancerAd libitumChemotherapy
2023
Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases
Upadhyay R, Klamer B, Perlow H, White J, Bazan J, Jhawar S, Blakaj D, Grecula J, Arnett A, Mestres-Villanueva M, Healy E, Thomas E, Chakravarti A, Raval R, Lustberg M, Williams N, Palmer J, Beyer S. Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases. Cancers 2023, 16: 137. PMID: 38201564, PMCID: PMC10778270, DOI: 10.3390/cancers16010137.Peer-Reviewed Original ResearchIntracranial progression-free survivalProgression-free survivalBreast cancer patientsBrain metastasesOverall survivalYounger patientsCancer patientsRadiation necrosisOlder womenOlder patientsPositive diseaseSystemic therapyMultivariable analysisTreatment patternsBiopsy-proven breast cancer patientsCox proportional hazards regression methodsIncidence of BMOlder breast cancer patientsSingle-institutional retrospective reviewTreatment-related adverse eventsAge groupsBreast cancer brain metastasesMetastatic breast cancer patientsWorse progression-free survivalProportional hazards regression methodsRetrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi C, Ruddy K, Cathcart-Rake E, Trovato S, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients. Supportive Care In Cancer 2023, 31: 717. PMID: 37991653, DOI: 10.1007/s00520-023-08160-0.Peer-Reviewed Original ResearchConceptsBreast cancer patientsTherapeutic responseAdverse eventsClinical characteristicsCancer patientsCommon cutaneous adverse eventsCutaneous adverse eventsPoor systemic absorptionRetrospective cohort studyComparison of pretreatmentEIA patientsEndocrine monotherapyClinical improvementCohort studyRetrospective cohortOncologic treatmentTopical antiandrogenCombination therapySystemic absorptionAndrogenetic alopeciaDean scaleMethodsThis studyPatientsAlopeciaScore gradeAwareness of racial/ethnic inequities in time to treatment among breast cancer providers.
Cohen I, Canavan M, Jacob A, Sondhi A, Silver H, Bramwell L, Lustberg M, Adelson K. Awareness of racial/ethnic inequities in time to treatment among breast cancer providers. JCO Oncology Practice 2023, 19: 584-584. DOI: 10.1200/op.2023.19.11_suppl.584.Peer-Reviewed Original ResearchBreast cancer providersCancer providersRace/ethnicityEthnic inequitiesTreatment inequitiesExact testSmilow Cancer HospitalYale Cancer CenterHospital-level factorsEducational interventionAdverse social determinantsFisher's exact testDe-identified databaseBrief educational interventionNon-Latinx WhitesPatient factorsWhite patientsProvider factorsCancer HospitalCancer CenterCancer patientsOncological careCare metricsClinical armTreatment metricsThe genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.
Lustberg M, Kaneva K, Teslow E, Mauer E, Federman N, Eisfeld A. The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing. Journal Of Clinical Oncology 2023, 41: e15091-e15091. DOI: 10.1200/jco.2023.41.16_suppl.e15091.Peer-Reviewed Original ResearchTriple-negative breast cancerTumor mutational burdenCancer patientsAYA patientsMicrosatellite instabilityBreast cancerNext-generation sequencingYoung adult cancer patientsYoung adult malignancyColorectal cancer patientsAdult cancer patientsHER2- breast cancerOlder adult patientsAYA cancer patientsSoft tissue sarcomasCentral nervous systemHigh-grade gliomasLow-grade gliomasPathogenic single nucleotide variantsAYA cancerSingle nucleotide variantsAdult patientsGastrointestinal malignanciesNTRK fusionsAML subgroupsQuantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Kwan J, Arbune A, Henry M, Hu R, Wei W, Nguyen V, Lee S, Lopez-Mattei J, Guha A, Huber S, Bader A, Meadows J, Sinusas A, Mojibian H, Peters D, Lustberg M, Hull S, Baldassarre L. Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients. PLOS ONE 2023, 18: e0286364. PMID: 37252927, PMCID: PMC10228774, DOI: 10.1371/journal.pone.0286364.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSystolic heart failureCardiovascular outcomesCancer patientsHeart failureValvular diseaseStrain abnormalitiesLeft ventricular ejection fraction reductionCancer treatment-related cardiotoxicityCardiovascular magnetic resonance findingsVentricular ejection fraction reductionYale-New Haven HospitalEjection fraction reductionTreatment-related cardiotoxicityAdverse cardiovascular outcomesClinical risk factorsNormal LV functionGlobal longitudinal strainIschemic heart diseaseMagnetic resonance findingsRisk regression modelsNew Haven HospitalSubclinical cardiotoxicityDiastolic dysfunctionStatin useRetrospective cohort study of scalp cooling in breast cancer patients
Rose L, Schnell P, Radcliff L, Lustberg M, Dulmage B. Retrospective cohort study of scalp cooling in breast cancer patients. Supportive Care In Cancer 2023, 31: 118. PMID: 36645520, DOI: 10.1007/s00520-022-07562-w.Peer-Reviewed Original ResearchConceptsScalp coolingChemotherapy regimenPatient ageInsurance statusRetrospective cohort studyCommon side effectsRetrospective chart reviewNon-white patientsBreast cancer patientsStage of cancerQuality of lifeChart reviewCohort studyWhite patientsPatient's likelihoodChemotherapy infusionCancer patientsTreatment optionsOncology settingBreast cancerPatient decisionSide effectsPatientsTreatment planHealthcare providers
2022
Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity
Nepal M, Taheri H, Li Y, Talebi Z, Uddin M, Jin Y, DiGiacomo D, Gibson A, Lustberg M, Hu S, Sparreboom A. Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity. Cancer Research Communications 2022, 2: 1334-1343. PMID: 36506732, PMCID: PMC9730833, DOI: 10.1158/2767-9764.crc-22-0172.Peer-Reviewed Original ResearchConceptsDRG neuronsPeripheral neurotoxicitySide effectsOxaliplatin-Induced Peripheral NeurotoxicityOxaliplatin-based regimensOxaliplatin-based treatmentPharmacokinetics of oxaliplatinEffect of duloxetineMouse DRG neuronsWild-type miceCytotoxicity of oxaliplatinConcentration-dependent mannerColorectal cancerCancer patientsPlasma levelsOIPNPlasma pharmacokineticsDuloxetinePrevention strategiesTherapeutic candidateOxaliplatinTumor cell linesTranslational feasibilityMiceComplete protectionThe Effects of Chemotherapy on Circulating Plasma Omega-9, Omega-3 Fatty Acids and Plasmalogen in Breast Cancer Patients
Bennouna D, Orchard T, Lustberg M, Kopec R. The Effects of Chemotherapy on Circulating Plasma Omega-9, Omega-3 Fatty Acids and Plasmalogen in Breast Cancer Patients. Current Developments In Nutrition 2022, 6: 6009237. PMCID: PMC9193887, DOI: 10.1093/cdn/nzac052.004.Peer-Reviewed Original ResearchPlasma concentrationsCognitive impairmentLong-term cognitive impairmentNutritional targetsDocosahexaenoic acidNervonic acidEicosapentaenoic acidOmega-3 fatty acidsNeo-adjuvant chemotherapyBreast cancer patientsEffect of chemotherapyBreast cancer chemotherapyFatty acidsBreast cancer treatmentHippocampal concentrationsDietary interventionSolid tumor treatmentCancer patientsChemotherapy treatmentFatty acid concentrationsObjective biomarkersBreast cancerImpact of visitsChemotherapyMead acid
2021
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis
Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, Addison D. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. European Heart Journal 2021, 43: 300-312. PMID: 34791123, PMCID: PMC8914878, DOI: 10.1093/eurheartj/ehab745.Peer-Reviewed Original ResearchConceptsNew-onset atrial fibrillationBreast cancer patientsBreast cancer diagnosisAtrial fibrillationCancer patientsBreast cancer stageRisk factorsBreast cancerCardiovascular mortalityCancer stageCancer diagnosisAF incidenceBreast cancer-related mortalityDevelopment of AFCox proportional hazards modelNew primary diagnosisOnset atrial fibrillationRisk survival statisticsSEER-Medicare analysisCardiovascular risk factorsEnd Results-MedicarePrevalent atrial fibrillationKaplan-Meier methodUnited States cohortCancer-related mortalityExamining the Association of Billed Advance Care Planning With End-of-Life Hospital Admissions Among Advanced Cancer Patients in Hospice
Prater LC, O’Rourke B, Schnell P, Xu W, Li Y, Gustin J, Lockwood B, Lustberg M, White S, Happ MB, Retchin SM, Wickizer TM, Bose-Brill S. Examining the Association of Billed Advance Care Planning With End-of-Life Hospital Admissions Among Advanced Cancer Patients in Hospice. American Journal Of Hospice And Palliative Medicine® 2021, 39: 504-510. PMID: 34427154, DOI: 10.1177/10499091211039449.Peer-Reviewed Original ResearchConceptsAdvance care planningDays of lifeHospital admissionAdvanced cancerCare planningACP servicesCross-sectional retrospective cohort studySystematic advance care planningLife hospital admissionsMedical claims analysisRetrospective cohort studyAdvanced cancer patientsInpatient hospital admissionsPopulation of patientsAdvanced cancer diagnosisQuality of careHospice referralCohort studyIBM MarketScanEOL outcomesInpatient admissionsStudy criteriaCancer patientsHospice careCare preferencesErythrocyte Long-Chain ω-3 Fatty Acids Are Positively Associated with Lean Mass and Grip Strength in Women with Recent Diagnoses of Breast Cancer
Belury MA, Cole RM, Andridge R, Keiter A, Raman SV, Lustberg MB, Kiecolt-Glaser JK. Erythrocyte Long-Chain ω-3 Fatty Acids Are Positively Associated with Lean Mass and Grip Strength in Women with Recent Diagnoses of Breast Cancer. Journal Of Nutrition 2021, 151: 2125-2133. PMID: 34036350, PMCID: PMC8349126, DOI: 10.1093/jn/nxab109.Peer-Reviewed Original ResearchConceptsPostprandial energy metabolismGrip strengthAppendicular lean massBreast cancerLean massCardiorespiratory fitnessCancer stageTest mealCancer treatmentPostprandial substrate metabolismBreast cancer survivorsLong-chain omega-3Risk of mortalityFat test mealALM/BMIFatty acidsLong chain ωCross-sectional analysisEnergy metabolismLCn-3PUFACancer survivorsCancer patientsMetabolic outcomesRecent diagnosisSame visitThe Effects of Chemotherapy on Circulating Plasma Carotenoids and Fat-Soluble Vitamins in Breast Cancer Patients
Bennouna D, Orchard T, Lustberg M, Kopec R. The Effects of Chemotherapy on Circulating Plasma Carotenoids and Fat-Soluble Vitamins in Breast Cancer Patients. Current Developments In Nutrition 2021, 5: 70. PMCID: PMC8180829, DOI: 10.1093/cdn/nzab034_004.Peer-Reviewed Original ResearchFat-soluble vitaminsNSAID useMultivitamin useNon-steroidal anti-inflammatory drug useAnti-inflammatory drug useNeo-adjuvant chemotherapyBreast cancer patientsPro-inflammatory cytokinesEffect of chemotherapyFat-soluble vitamin concentrationsBreast cancer chemotherapyMethods Serum samplesFree-living patientsChemotherapy commencementSerum luteinSerum retinolCancer patientsSerum concentrationsChemotherapy treatmentInflammatory processBreast cancerMerit further investigationChemotherapyPlasma carotenoidsDrug useChanges in Serum Fatty Acids and Inflammatory Markers in Postmenopausal Women With Breast Cancer Following Chemotherapy Treatment
Zhang Z, Ormiston K, Schnell P, Kopec R, Lustberg M, Orchard T. Changes in Serum Fatty Acids and Inflammatory Markers in Postmenopausal Women With Breast Cancer Following Chemotherapy Treatment. Current Developments In Nutrition 2021, 5: 5140290. PMCID: PMC8182042, DOI: 10.1093/cdn/nzab036_032.Peer-Reviewed Original ResearchSerum fatty acidsInflammatory markersInterleukin-6Breast cancerSerum cytokinesPostmenopausal breast cancer patientsSerum inflammatory markersBreast cancer survivorsBreast cancer patientsFatty acidsMethods Serum samplesTumor necrosis factorTotal monounsaturated FAsTotal monounsaturated fatty acidsEnzyme-linked immunoassaySerum FCytokine changesPostmenopausal womenInflammatory profileCancer survivorsInflammatory stateCancer patientsIL-8Chemotherapy treatmentNecrosis factorDelay Discounting and Adjuvant Endocrine Therapy Adherence in Hormone Receptor-Positive Breast Cancer
Vaughn JE, Ammermann C, Lustberg MB, Bickel WK, Stein JS. Delay Discounting and Adjuvant Endocrine Therapy Adherence in Hormone Receptor-Positive Breast Cancer. Health Psychology 2021, 40: 398-407. PMID: 34323542, DOI: 10.1037/hea0001077.Peer-Reviewed Original ResearchConceptsEndocrine therapy adherenceTherapy adherenceHormone receptor-positive breast cancerAdjuvant endocrine therapy adherenceReceptor-positive breast cancerOral endocrine therapyBreast cancer survivorsBreast cancer patientsSelf-reported adherencePatient-centered factorsBrief behavioral interventionCross-sectional associationsPotential therapeutic targetMaladaptive health behaviorsEndocrine therapyMedication nonadherenceCancer survivorsCancer patientsRisk factorsBreast cancerTherapeutic targetHealth behaviorsPatientsBehavioral interventionsSurvivorsA Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility Study
Zvinovski F, Stephens JA, Ramaswamy B, Reinbolt RE, Noonan AM, VanDeusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Mehta L, Foraker R, Gulati M, Lustberg M, Quick AM. A Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility Study. Journal Of Oncology 2021, 2021: 9965583. PMID: 34135964, PMCID: PMC8178006, DOI: 10.1155/2021/9965583.Peer-Reviewed Original ResearchBreast cancer survivorsSerious adverse eventsBrief Fatigue InventoryCancer survivorsQLQ-C30Risk factorsStudy protocolSingle-arm feasibility studyCardiovascular disease risk factorsVO2 maxCVD risk factorsCardiac rehabilitation programDisease risk factorsCardiac rehabilitation interventionsBreast cancer populationQuality of lifeSecondary endpointsAdverse eventsCR programPreliminary efficacyCancer patientsCancer populationFatigue InventoryOverall adherenceMean changeGenetic testing documentation in survivorship care plans in patients with breast cancer.
Kaur K, Shinde N, Klemanski D, Xu M, Aeilts A, Lustberg M, Jeter J. Genetic testing documentation in survivorship care plans in patients with breast cancer. Journal Of Clinical Oncology 2021, 39: e24110-e24110. DOI: 10.1200/jco.2021.39.15_suppl.e24110.Peer-Reviewed Original ResearchSurvivorship care plansGenetic testing resultsSCP templatesGenetic testingBreast cancerCare plansResult groupGermline mutationsRetrospective chart reviewBreast cancer patientsTest result groupOncology treatment teamNon-Hispanic whitesExtent of documentationCancer genetic testingGenetic counselorsSurvivorship visitChart reviewMedian ageCancer survivorsCancer patientsResult categoriesInvolved genesHereditary predispositionTreatment teamDissemination of cancer survivorship care plans: who is being left out?
Timsina LR, Zarzaur B, Haggstrom DA, Jenkins PC, Lustberg M, Obeng-Gyasi S. Dissemination of cancer survivorship care plans: who is being left out? Supportive Care In Cancer 2021, 29: 4295-4302. PMID: 33415363, DOI: 10.1007/s00520-020-05915-x.Peer-Reviewed Original ResearchConceptsSurvivorship care plansCancer survivorsCare plansComprehensive survivorship care planCancer survivorship care plansLow educational achievementMultivariable logistic regressionSelf-reported receiptQuality of careAssociation of SDOHYounger patientsSurgeons CommissionCancer patientsPrimary careAmerican CollegeAdult populationSocial determinantsLogistic regressionPatientsSurvivorsLower likelihoodMarital statusCareFuture studiesReceipt
2020
Worry and rumination in breast cancer patients: perseveration worsens self-rated health
Renna ME, Rosie Shrout M, Madison AA, Lustberg M, Povoski SP, Agnese DM, Reinbolt RE, Wesolowski R, Williams NO, Ramaswamy B, Sardesai SD, Noonan AM, VanDeusen JB, Malarkey WB, Kiecolt-Glaser JK. Worry and rumination in breast cancer patients: perseveration worsens self-rated health. Journal Of Behavioral Medicine 2020, 44: 253-259. PMID: 33135103, PMCID: PMC8272958, DOI: 10.1007/s10865-020-00192-9.Peer-Reviewed Original ResearchConceptsSelf-rated healthBreast cancer patientsBreast Cancer Prevention Trial Symptom ChecklistCancer-related distressBreast cancer symptomsPoor physical functioningPhysical functioningCancer patientsPhysical symptomsAdjuvant treatmentCancer symptomsGreater cancer-related distressHigher cancer-related distressGreater painLower self-rated healthBody mass indexQuality of lifePhysical comorbiditiesMass indexRAND-36Menopause statusCancer stageCancer trajectorySymptom ChecklistSymptoms